Clinical Report: Assessing the Impact of a Novel Spectacle Lens for Myopia Management
Overview
This study evaluates the effectiveness of the Shamir Myopia Control (SMC) lens in slowing myopia progression in children over 24 months. Results indicate significant reductions in axial length elongation compared to conventional single-vision lenses.
Background
Myopia is a growing public health issue, associated with severe ocular complications. Effective management strategies are crucial to mitigate its progression, particularly in children. The introduction of innovative spectacle lenses, such as the SMC lens, aims to address this challenge by inducing myopic defocus on the peripheral retina.
Data Highlights
No numerical data available in the provided material.
Key Findings
The SMC lens features a unique U-shaped design that induces peripheral myopic defocus.
Participants wearing SMC lenses showed reduced axial length elongation compared to those with single-vision lenses.
The study involved 126 myopic children aged 6-13 years, monitored over 24 months.
Significant improvements in visual comfort and subjective experiences were reported by participants wearing the SMC lenses.
Children with a spherical equivalent progression of more than 1 diopter per year were excluded and referred for alternative treatments.
Clinical Implications
The findings support the use of SMC lenses as a viable option for myopia management in children, potentially reducing the risk of future ocular complications. Clinicians should consider integrating such lenses into treatment plans for myopic children to enhance visual outcomes.
Conclusion
The SMC lens demonstrates promise in effectively managing myopia progression in children over a 24-month period. Further studies are warranted to confirm long-term efficacy and safety.
Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia
